Several drug companies could see the prices of their best-selling treatments reduced in Germany as the Federal Joint Committee evaluates their cost-effectiveness. The list covers treatment areas including rheumatoid arthritis, osteoporosis, diabetes and pain. The reviews are being done under a system begun in 2011 to base prices on cost-benefit analyses.

Full Story:

Related Summaries